Loading data for PRAX — first visit, this takes a few seconds.

Praxis Precision Medicines, Inc. (PRAX)

NasdaqGS: PRAX · Real-Time Price · USD

344.75

-23.10 (-6.28%)

At close: Sep 01, 2026, 8:00 PM

352.09

-0.38%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	372.31
Market Cap	9.87B
Revenue (ttm)	n/a
Net Income (ttm)	-339M
	2.78
	-12.96
	n/a
	-38.03
P/B (ttm)	7.36
P/S (ttm)	0.00
Earnings Date	Nov 9, 2026

Ask	376.24
Volume	282,850
Avg. Volume (20D)	503,117
Open	363.40
Previous Close	367.85
Day's Range	344.69 - 367.70
52-Week Range	37.19 - 392.70
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleoti...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2020

Employees 168

Stock Exchange NasdaqGS

Ticker Symbol PRAX

Website https://praxismedicines.com

Full Company Profile

Financial Performance

In 2025, Praxis Precision Medicines's revenue was 0, a decrease of -100% compared to the previous year's 8.55M. Earnings were -303.27M, an increase of 65.88%.

Financial Statements

Earnings Surprise

Praxis Precision Medicines has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -2.87 exceeds estimates by 0.82, with 13.29% YoY growth.

Next Earnings Release

Praxis Precision Medicines, Inc. is scheduled to release its earnings on Nov 9, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · Motley Fool

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Two FDA applications advance as cash runway extends into 2028.

3 weeks ago · Zacks

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

3 weeks ago · Simply Wall St.

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

Praxis Precision Medicines reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while reaffirming its focus ...

3 weeks ago · Moby

Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary

Moby summary of Praxis Precision Medicines, Inc.'s Q2 2026 earnings call

3 weeks ago · MarketBeat

Praxis Precision Medicines Q2 Earnings Call Highlights

Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and ep...

Page 1 of 2

Praxis Precision Medicines, Inc. (PRAX)